title: [Single center experience of (18F)-fluorocholine positron emission tomography: analysis of its impact on salvage local therapy in patients with prostate adenocarcinoma].
abstract: OBJECTIVE
  To assess usefulness of ((18)F)-fluorocholine positron emission tomography (PET) for localizing relapse in patients with biochemical relapse from prostate adenocarcinoma and its impact on indications of salvage local therapy.
  
  
  METHODS
  An ((18)F)-fluorocholine PET coupled with computed tomography was performed in 28 patients with biochemical progression from prostate adenocarcinoma. At the time of ((18)F)-fluorocholine PET, median prostate specific antigen (PSA) was 3.0 ng/mL (from 0.34 to 93 ng/mL) and 17 patients (60.7%) received hormone therapy. Eighteen patients from this cohort were potentially candidates to salvage radiotherapy.
  
  
  RESULTS
  A pathologic uptake was shown in 11 patients (39.3%) and 17 patients (60.7%) had no pathologic uptake. Median PSA was 2.4 ng/mL (0.33 to 36 ng/mL) in case of negative ((18)F)-fluorocholine PET, versus 6.75 ng/mL (1.21 to 93 ng/mL) in case of pathologic uptake (P=0.04). Among the 17 patients candidates to salvage radiotherapy, ((18)F)-fluorocholine PET helped deciding for salvage radiotherapy in five patients, since it showed only centropelvic pathologic uptake (27.7%). In one patient, it showed metastatic and radiotherapy was contraindicated. After prostatectomy, ((18)F)-fluorocholine PET was positive in only one patient candidate to salvage radiotherapy (9.1%), showing anastomotic relapse.
  
  
  CONCLUSIONS
  ((18)F)-fluorocholine was positive in about a third of patients with biochemical progression. Its clinical impact is being prospectively investigated.
authors.affiliation: Service d'Oncologie Radiothérapie, Hôpital d'Instruction des Armées du Val-de-Grâce, 74 boulevard de Port-Royal, 75005 Paris, France.
authors.forename: Y
authors.initials: Y
authors.lastname: Moussaid
authors.forename: G
authors.initials: G
authors.lastname: Bonardel
authors.forename: J
authors.initials: J
authors.lastname: Jacob
authors.forename: D
authors.initials: D
authors.lastname: Métivier
authors.forename: E
authors.initials: E
authors.lastname: Gontier
authors.forename: O
authors.initials: O
authors.lastname: Bauduceau
authors.forename: X
authors.initials: X
authors.lastname: Durand
authors.forename: M
authors.initials: M
authors.lastname: Fayolle
authors.forename: A
authors.initials: A
authors.lastname: Houlgatte
authors.forename: H
authors.initials: H
authors.lastname: Foehrenbach
authors.forename: L
authors.initials: L
authors.lastname: Védrine
authors.forename: C
authors.initials: C
authors.lastname: Chargari
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary* / Q000601:surgery; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D002794:Choline / Q000031:analogs & derivatives*; D003131:Combined Modality Therapy; D005462:Fluorine Radioisotopes; D057086:High-Intensity Focused Ultrasound Ablation; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging* / Q000532:radiotherapy; D018579:Patient Selection; D049268:Positron-Emission Tomography; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012189:Retrospective Studies; D016879:Salvage Therapy; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; C514960:fluorocholine; D017430:Prostate-Specific Antigen; D002794:Choline
keywords: ((18)F)-fluorocholine; ((18)F)-fluorocholine PET; Adénocarcinome prostatique; Positron emission tomography; Prostate adenocarcinoma; Radiation therapy; Radiothérapie; Tomographie par émission de positons